Payment overview · 2025
General Payments
$780.56
44 reported records · 20 companies
Healthcare provider profile · identity verified
Zeinab Harb
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · DEARBORN, MI · NPI 1790450344
Verified facts
What the public records show
CMS Open Payments records show Zeinab Harb received $780.56 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.57 | 19.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.98 | 10.5% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $73.24 | 9.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.26 | 8.4% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $43.34 | 5.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.49 | 5.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.63 | 4.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.13 | 4.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.78 | 4.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.92 | 4.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.02 | 3.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $23.40 | 3.0% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.81 | 2.5% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $18.75 | 2.4% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $16.55 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.21 | 2.1% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $16.07 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.35 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.06 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $780.56 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $73.24 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.33 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.14 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.35 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.13 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| JUXTAPID Normalized: juxtapid |
Drug | Chiesi USA, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 67 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
67 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
67 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 115 |
| Omeprazole | Omeprazole | 278 | 104 |
| Losartan Potassium | Losartan Potassium | 173 | 69 |
| Metformin Hcl | Metformin Hcl | 160 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 48 |
| Jardiance | Empagliflozin | 97 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 62 |
| Montelukast Sodium | Montelukast Sodium | 90 | 31 |
| Simvastatin | Simvastatin | 85 | 34 |
| Gabapentin | Gabapentin | 84 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 38 |
| Lisinopril | Lisinopril | 81 | 29 |
| Ibuprofen | Ibuprofen | 71 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 27 |
| Linzess | Linaclotide | 67 | 28 |
| Azithromycin | Azithromycin | 65 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 53 | 28 |
| Glipizide | Glipizide | 51 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 26 |
| Farxiga | Dapagliflozin Propanediol | 48 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 16 |
| Alendronate Sodium | Alendronate Sodium | 40 | 13 |
| Meclizine Hcl | Meclizine Hcl | 39 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 20 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 37 | 17 |
| Alprazolam | Alprazolam | 36 | 15 |
| Sertraline Hcl | Sertraline Hcl | 36 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 12 |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Eliquis | Apixaban | 29 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | 12 |
| Potassium Chloride | Potassium Chloride | 28 | 12 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 12 |
| Myrbetriq | Mirabegron | 27 | 11 |
| Prednisone | Prednisone | 27 | 22 |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Furosemide | Furosemide | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | 12 |
| Carvedilol | Carvedilol | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 11 |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Naproxen | Naproxen | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $780.56 · 44 records | Novo Nordisk Inc | APTIMA, BREZTRI, BRIXADI, CAPLYTA, Cologuard Collection Kit, GEMTESA, IBSRELA, JARDIANCE, JUXTAPID, KISUNLA, Linzess, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, SUBLOCADE, Symbravo, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error